Skip to content
AwardedRomaniaServicesRON 75,000

Servicii de Secventiere Genomica, necesare pentru efectuarea activitatilor de cercetare in cadrul poiectului de cercetare PNRR-III-C9-2023-I8, Contract de finanţare nr. 760278/26.03.2024, cu titlul "Creating a Research Group of Excellence to develop cell and immune therapy technology to target the tumor microenvironment"

Published
Published 2 March 2026
Deadline
Closed 30 March 2026

Overview

Universitatea de Medicina si Farmacie "Iuliu Hatieganu" Cluj-Napoca procured genomic sequencing services for research activities under the PNRR-III-C9-2023-I8 research project focused on developing cell and immune therapy technology to target the tumor microenvironment. The contract was awarded to MEDLIFE on 6 May 2026 for 65,000 RON.

Key details

Country
Romania
Status
Awarded
Category
Services
Estimated value
RON 75,000
Procedure
Open
Published
2 March 2026
Deadline
Closed
Classification (CPV)
Research services

Award outcome

Awarded value
RON 65,000
Award date
6 May 2026
Contract period
— → 30 June 2026
Winner
  • MEDLIFE

Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.

Notice history

Every published notice in this contracting process, newest first.

  1. Contract Award Notice

    28 May 2026

  2. Contract Notice

    2 March 2026

Contracting authority

  • Universitatea de Medicina si Farmacie "Iuliu Hatieganu" Cluj-Napoca

    Procuring entity

    Cluj-Napoca, Romania

    Authority website ↗

Get the full picture

AI analysis, bid scoring, and expert strategy for this tender

Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.

See which competitors are winning the contracts you're chasing.

15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.

Awarded: Servicii de Secventiere Genomica, necesare pentru efectuarea activitatilor de cercetare in cadrul poiectului de cercetare PNRR-III-C9-2023-I8, Contract de finanţare nr. 760278/26.03.2024, cu titlul "Creating a Research Group of Excellence to develop cell and immune therapy technology to target the tumor microenvironment" — won by MEDLIFE — Skim